Amylyx Pharmaceuticals, Inc. AMLX Short- and long-term operating lease liabilities
Short- and long-term operating lease liabilities at other companies
Other financials
Where this comes from
Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.
The official record: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amylyx Pharmaceuticals, Inc.'s short- and long-term operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amylyx Pharmaceuticals, Inc.'s short- and long-term operating lease liabilities?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported short- and long-term operating lease liabilities of -$327K in Q1 2026.
- How has Amylyx Pharmaceuticals, Inc.'s short- and long-term operating lease liabilities changed year-over-year?
- Amylyx Pharmaceuticals, Inc.'s short- and long-term operating lease liabilities increased by 45.4% year-over-year, from -$599K to -$327K.
- What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s short- and long-term operating lease liabilities?
- Over 3 years (2022 to 2025), Amylyx Pharmaceuticals, Inc.'s short- and long-term operating lease liabilities has grown at a 8.9% compound annual growth rate (CAGR), from -$917K to -$1.19M.